GK
Gary K. Lee
Chief Scientific OfficerDr. Gary K. Lee, Ph.D., was the Chief Scientific Officer at Senti Biosciences, Inc. since 2018 until January 2022. He serves as Chief Scientific Officer at Lyell Immunopharma, Inc. since January 2022. He served as Senior Director of Genome Editing and VP of Cell Therapy at Sangamo Therapeutics, Inc. Dr. Lee also served as the head of Sangamo’s immunology/Treg therapeutic pipeline. Dr. Lee received his B.S. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from University of California Berkeley.
Positions
- Company NameLyell Immunopharma, Inc.Stock CodeLYELPositionChief Scientific OfficerColleagues
- RDRichard D. KlausnerFounder & Executive Chairman
- LSLynn SeelyPrincipal Executive Officer, President, CEO & Director
- SJStephen J. HillChief Operating Officer
- SRStanley R. RiddellFounder & Scientific Advisor
- CJCatherine J. FriedmanLead Independent Director
- WJWilliam JL RieflinIndependent Director
- OWOtis Webb BrawleyIndependent Director
